View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMyovant Sciences 将来の成長Future 基準チェック /56主要情報59.0%収益成長率n/aEPS成長率Biotechs 収益成長22.8%収益成長率27.6%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日10 Mar 2023今後の成長に関する最新情報Breakeven Date Change • May 12No longer forecast to breakevenThe 5 analysts covering Myovant Sciences no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$110.5m in 2025. New consensus forecast suggests the company will make a loss of US$74.9m in 2025.Breakeven Date Change • Jan 28Forecast to breakeven in 2024The 5 analysts covering Myovant Sciences expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 21% per year to 2023. The company is expected to make a profit of US$9.26m in 2024. Average annual earnings growth of 69% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesRecent Insider Transactions • Sep 21Principal Financial Officer recently sold €174k worth of stockOn the 16th of September, Uneek Mehra sold around 9k shares on-market at roughly €18.82 per share. This transaction amounted to 4.3% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €559k. This was Uneek's only on-market trade for the last 12 months.Recent Insider Transactions • Aug 18General Counsel & Corporate Secretary recently sold €559k worth of stockOn the 15th of August, Matthew Lang sold around 31k shares on-market at roughly €17.90 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.0m more than they bought in the last 12 months.Reported Earnings • Jul 29First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.67 loss in 1Q 2022)First quarter 2023 results: US$0.22 loss per share (up from US$0.67 loss in 1Q 2022). Revenue: US$116.5m (up 184% from 1Q 2022). Net loss: US$21.2m (loss narrowed 66% from 1Q 2022). Over the next year, revenue is forecast to grow 47%, compared to a 31% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 25% per year.Recent Insider Transactions • Jul 22CEO & Director recently sold €141k worth of stockOn the 18th of July, David Marek sold around 11k shares on-market at roughly €12.66 per share. This was the largest sale by an insider in the last 3 months. David has been a seller over the last 12 months, reducing personal holdings by €637k.Breakeven Date Change • May 12No longer forecast to breakevenThe 5 analysts covering Myovant Sciences no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$110.5m in 2025. New consensus forecast suggests the company will make a loss of US$74.9m in 2025.Reported Earnings • May 11Full year 2022 earnings released: US$2.22 loss per share (vs US$2.83 loss in FY 2021)Full year 2022 results: US$2.22 loss per share (up from US$2.83 loss in FY 2021). Revenue: US$231.0m (up 289% from FY 2021). Net loss: US$206.0m (loss narrowed 19% from FY 2021). Over the next year, revenue is forecast to grow 85%, compared to a 37% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Nancy Valente was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Apr 22General Counsel & Corporate Secretary recently sold €77k worth of stockOn the 19th of April, Matthew Lang sold around 8k shares on-market at roughly €9.68 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.0m more than they bought in the last 12 months.Breakeven Date Change • Jan 28Forecast to breakeven in 2024The 5 analysts covering Myovant Sciences expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 21% per year to 2023. The company is expected to make a profit of US$9.26m in 2024. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Recent Insider Transactions • Jan 22CEO & Director recently sold €257k worth of stockOn the 19th of January, David Marek sold around 20k shares on-market at roughly €12.93 per share. This was the largest sale by an insider in the last 3 months. This was David's only on-market trade for the last 12 months.Recent Insider Transactions • Jan 07General Counsel & Corporate Secretary recently sold €64k worth of stockOn the 4th of January, Matthew Lang sold around 4k shares on-market at roughly €14.40 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.1m more than they bought in the last 12 months.Recent Insider Transactions • Oct 08General Counsel & Corporate Secretary recently sold €124k worth of stockOn the 5th of October, Matthew Lang sold around 7k shares on-market at roughly €18.62 per share. In the last 3 months, they made an even bigger sale worth €126k. Insiders have been net sellers, collectively disposing of €974k more than they bought in the last 12 months.Board Change • Aug 05Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Lead Independent Director Kathleen Sebelius was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Jul 11Key Executive recently sold €60k worth of stockOn the 7th of July, Frank Karbe sold around 3k shares on-market at roughly €18.44 per share. This was the largest sale by an insider in the last 3 months. Frank has been a seller over the last 12 months, reducing personal holdings by €234k.Recent Insider Transactions • Apr 09General Counsel & Corporate Secretary recently sold €171k worth of stockOn the 6th of April, Matthew Lang sold around 11k shares on-market at roughly €15.72 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €351k more than they bought in the last 12 months.Is New 90 Day High Low • Mar 06New 90-day low: €16.40The company is down 16% from its price of €19.60 on 04 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €192 per share.Is New 90 Day High Low • Dec 17New 90-day high: €21.40The company is up 24% from its price of €17.30 on 18 September 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €153 per share.Is New 90 Day High Low • Dec 02New 90-day high: €20.00The company is up 17% from its price of €17.10 on 03 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €122 per share.お知らせ • Sep 30Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate CancerMyovant Sciences announced results of an additional secondary endpoint from the Phase 3 HERO study evaluating relugolix in men with advanced prostate cancer. Relugolix did not achieve statistical superiority for castration resistance-free survival compared to leuprolide acetate in men with metastatic disease through 48 weeks. Castration-resistant prostate cancer is defined by disease progression despite achieving testosterone suppression to castrate levels (< 50 ng/dL). In the subgroup of men with metastatic disease treated with relugolix, 74% were castration-resistance free through 48 weeks compared to 75% men treated with leuprolide acetate (HR = 1.03 [95% CI: 0.68-1.57]; p = 0.84). In the secondary endpoint analysis, castration resistance-free survival was defined as the time from first dose to prostate-specific antigen (PSA) progression per the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria or death from any cause. PSA progression was defined as a PSA increase = 25% and = 2 ng/mL above the nadir, and confirmed by a second PSA value = 3 weeks later.お知らせ • Sep 24Myovant Sciences Launches 'Forward for Health Equity' Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine FibroidsMyovant Sciences announced the launch of its 'Forward for Health Equity' grant program. The program will provide funding to nonprofit healthcare organizations with innovative projects focused on improving healthcare access, with an initial focus on reducing racial disparities in prostate cancer and uterine fibroids in the U.S.Myovant will award as many as four grants of up to $50,000 each, for a total of $200,000. Prostate cancer is the second deadliest cancer in men in the U.S. and has the largest racial disparity of any major cancer, killing Black men twice as often as white men. Uterine fibroids can cause debilitating symptoms such as heavy menstrual bleeding and pain, leading to over 250,000 hysterectomies each year in the U.S., with Black women more likely to undergo more invasive surgical procedures. Studies have also shown that Black men and women have less access to healthcare, and access issues such as lack of insurance coverage have been shown to contribute to the racial disparities in prostate cancer and uterine fibroids. Myovant previously launched the Female Forward Together coalition in partnership with Evidation Health, Flo Health, HealthyWomen, and PERIOD, with coalition projects including the development of a digital tool to evaluate menstrual blood loss and the creation of a storytelling initiative to reduce stigma around menstruation. Myovant also recently launched the Forward Momentum coalition in partnership with BlackDoctor.org, Evidation Health, and Movember to improve representation of Black men and women in research studies and to develop digital tools for men with prostate cancer. The “Forward for Health Equity” grant program will accept applications through December 31, 2020. Applicants must be U.S.-based nonprofit healthcare organizations. Applicants may not be individual healthcare professionals. Applications will be evaluated based on 1) greatest potential to improve health equity, 2) degree of innovation, and 3) focus on healthcare access. Applications will be reviewed by a committee consisting of Myovant employees and external leaders and advocates.Is New 90 Day High Low • Sep 23New 90-day high: €19.40The company is up 10.0% from its price of €17.70 on 25 June 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €113 per share.お知らせ • Sep 15Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 Liberty Program and from Prospective Observational StudyMyovant Sciences announced the presentation of one-year data on bone mineral density (BMD) from the Phase 3 LIBERTY program evaluating the safety and efficacy of once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with uterine fibroids. The BMD results from the LIBERTY program demonstrated maintenance of BMD through one year and were consistent with those observed in a separate prospective observational study of untreated, age-matched women with uterine fibroids. The findings were presented at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event, held September 11-15, 2020. Details of the presentations are as follows: Relugolix Combination Therapy Preserves Bone Mass in Patients with Uterine Fibroids: Results from Phase 3 LIBERTY Program (Abstract # P-641). The Phase 3 LIBERTY program evaluated the safety and efficacy of once-daily relugolix combination therapy in premenopausal women with heavy menstrual bleeding due to uterine fibroids. The program met its primary endpoints and demonstrated that relugolix combination therapy significantly reduced menstrual blood loss and pain. In this analysis, pooled data from 768 women in the LIBERTY 1 and LIBERTY 2 studies showed that mean changes in lumbar spine bone mineral density (LS BMD) were comparable for relugolix combination therapy and placebo (Week 12: -0.63% vs. 0.34%; Week 24: -0.23% vs. 0.18%, respectively). Evaluation of Relugolix Combination Therapy to Maintain Bone Mass in Women with Uterine Fibroids Through 52 Weeks: LIBERTY Long-Term Extension Study (Abstract # P-639). Eligible women who completed the LIBERTY 1 or LIBERTY 2 studies were offered the opportunity to enroll in an active treatment extension study in which all women received relugolix combination therapy for an additional 28-week period, for a total treatment period of up to 52 weeks. In this analysis, data from 163 women who entered the extension study after receiving 24 weeks of relugolix combination therapy demonstrated maintenance of BMD through 52 weeks of treatment (Week 52: LS BMD -0.80%). A Prospective Observational Study of Bone Mineral Density in Premenopausal Women with Uterine Fibroids (Abstract # P-552). This prospective observational study was designed to characterize longitudinal BMD in 262 premenopausal women with uterine fibroids. Mean LS BMD showed minimal changes over the 52-week observational period (0% at Week 24 and -0.41% at Week 52). Relugolix combination tablet is under review by the U.S. Food and Drug Administration (FDA) for the treatment of women with uterine fibroids, with a target action date of June 1, 2021. Myovant submitted a Marketing Authorization Application to the European Medicines Agency in March 2020 for relugolix combination tablet in uterine fibroids. Additionally, relugolix (120 mg) is under Priority Review by the FDA for the treatment of men with advanced prostate cancer, with a target action date of December 20, 2020. Myovant has also reported positive data from two replicate Phase 3 studies evaluating relugolix combination therapy in women with endometriosis. Myovant’s Phase 3 clinical program for uterine fibroids consisted of two multinational, replicate pivotal clinical studies (LIBERTY 1 and LIBERTY 2) of relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with heavy menstrual bleeding associated with uterine fibroids for 24 weeks. Eligible women who completed the LIBERTY 1 or LIBERTY 2 studies were offered the opportunity to enroll in an active treatment extension study in which all women received relugolix combination therapy for an additional 28-week period for a total treatment period of 52 weeks, designed to evaluate the safety and efficacy of longer-term treatment. Upon completion of this 52-week total treatment period, eligible women could elect to participate in a second 52-week randomized withdrawal study designed to provide two-year safety and efficacy data on relugolix combination therapy and to evaluate the need for maintenance therapy. Across studies, a response was defined as a menstrual blood loss volume of less than 80 mL and a 50% or greater reduction from baseline in menstrual blood loss volume during the last 35 days of treatment measured using the alkaline hematin method. LIBERTY 1 and 2 met the primary endpoint (p < 0.0001) with 73.4% and 71.2% of women receiving relugolix combination therapy achieving the responder criteria compared with 18.9% and 14.7% of women receiving placebo at 24 weeks, respectively. On average, women receiving relugolix combination therapy in both studies experienced an 84.3% reduction in menstrual blood loss from baseline (p < 0.0001). Bone mineral density was comparable between the relugolix combination therapy and placebo groups in LIBERTY 1 and 2. The distribution of the change in bone mineral density, including outliers, was similar for the relugolix combination therapy and placebo groups at 24 weeks, as assessed by dual energy x-ray absorptiometry (DXA). The overall incidence of adverse events in the relugolix combination and placebo groups was comparable in both studies. The open-label extension study also met the primary endpoint with relugolix combination therapy demonstrating an 87.7% response rate at one year, showing the durability of the response observed in LIBERTY 1 and 2. In addition, women experienced, on average, an 89.9% reduction in menstrual blood loss from baseline. Changes in bone mineral density through one year, as assessed by DXA every three months, were consistent with LIBERTY 1 and 2. The incidence of adverse events over one year was consistent with that observed in LIBERTY 1 and 2, with no new safety signals observed.業績と収益の成長予測DB:71M - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2025618-74N/AN/A23/31/2024555-76N/AN/A33/31/2023418-153N/AN/A212/31/2022379-184-271-270N/A9/30/2022333-190-260-259N/A6/30/2022306-166-232-231N/A3/31/2022231-206-270-269N/A12/31/2021198-228-263-261N/A9/30/2021145-238403405N/A6/30/202167-284318319N/A3/31/202159-255369371N/A12/31/202035-239443444N/A9/30/202033-250-198-197N/A6/30/202033-254-217-216N/A3/31/2020N/A-289-222-221N/A12/31/2019N/A-299-256-255N/A9/30/2019N/A-284-252-250N/A6/30/2019N/A-279-247-246N/A3/31/2019N/A-274-225-224N/A12/31/2018N/A-247-207-206N/A9/30/2018N/A-218-176-175N/A6/30/2018N/A-182-136-135N/A3/31/2018N/A-143-118-117N/A12/31/2017N/A-117-94-93N/A9/30/2017N/A-83-70-69N/A6/30/2017N/A-88-46-45N/A3/31/2017N/A-83-19-18N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 71Mは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 0.2% ) よりも高い成長率であると考えられます。収益対市場: 71M今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: 71M今後 3 年以内に収益を上げることが予想されます。収益対市場: 71Mの収益 ( 27.6% ) German市場 ( 6.7% ) よりも速いペースで成長すると予測されています。高い収益成長: 71Mの収益 ( 27.6% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 71Mの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/03/13 05:44終値2023/03/09 00:00収益2022/12/31年間収益2022/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Myovant Sciences Ltd. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Brian SkorneyBairdMohit BansalCitigroup IncJason ButlerCitizens JMP Securities, LLC5 その他のアナリストを表示
Breakeven Date Change • May 12No longer forecast to breakevenThe 5 analysts covering Myovant Sciences no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$110.5m in 2025. New consensus forecast suggests the company will make a loss of US$74.9m in 2025.
Breakeven Date Change • Jan 28Forecast to breakeven in 2024The 5 analysts covering Myovant Sciences expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 21% per year to 2023. The company is expected to make a profit of US$9.26m in 2024. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Recent Insider Transactions • Sep 21Principal Financial Officer recently sold €174k worth of stockOn the 16th of September, Uneek Mehra sold around 9k shares on-market at roughly €18.82 per share. This transaction amounted to 4.3% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €559k. This was Uneek's only on-market trade for the last 12 months.
Recent Insider Transactions • Aug 18General Counsel & Corporate Secretary recently sold €559k worth of stockOn the 15th of August, Matthew Lang sold around 31k shares on-market at roughly €17.90 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.0m more than they bought in the last 12 months.
Reported Earnings • Jul 29First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.67 loss in 1Q 2022)First quarter 2023 results: US$0.22 loss per share (up from US$0.67 loss in 1Q 2022). Revenue: US$116.5m (up 184% from 1Q 2022). Net loss: US$21.2m (loss narrowed 66% from 1Q 2022). Over the next year, revenue is forecast to grow 47%, compared to a 31% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 25% per year.
Recent Insider Transactions • Jul 22CEO & Director recently sold €141k worth of stockOn the 18th of July, David Marek sold around 11k shares on-market at roughly €12.66 per share. This was the largest sale by an insider in the last 3 months. David has been a seller over the last 12 months, reducing personal holdings by €637k.
Breakeven Date Change • May 12No longer forecast to breakevenThe 5 analysts covering Myovant Sciences no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$110.5m in 2025. New consensus forecast suggests the company will make a loss of US$74.9m in 2025.
Reported Earnings • May 11Full year 2022 earnings released: US$2.22 loss per share (vs US$2.83 loss in FY 2021)Full year 2022 results: US$2.22 loss per share (up from US$2.83 loss in FY 2021). Revenue: US$231.0m (up 289% from FY 2021). Net loss: US$206.0m (loss narrowed 19% from FY 2021). Over the next year, revenue is forecast to grow 85%, compared to a 37% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Nancy Valente was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Apr 22General Counsel & Corporate Secretary recently sold €77k worth of stockOn the 19th of April, Matthew Lang sold around 8k shares on-market at roughly €9.68 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.0m more than they bought in the last 12 months.
Breakeven Date Change • Jan 28Forecast to breakeven in 2024The 5 analysts covering Myovant Sciences expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 21% per year to 2023. The company is expected to make a profit of US$9.26m in 2024. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Recent Insider Transactions • Jan 22CEO & Director recently sold €257k worth of stockOn the 19th of January, David Marek sold around 20k shares on-market at roughly €12.93 per share. This was the largest sale by an insider in the last 3 months. This was David's only on-market trade for the last 12 months.
Recent Insider Transactions • Jan 07General Counsel & Corporate Secretary recently sold €64k worth of stockOn the 4th of January, Matthew Lang sold around 4k shares on-market at roughly €14.40 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.1m more than they bought in the last 12 months.
Recent Insider Transactions • Oct 08General Counsel & Corporate Secretary recently sold €124k worth of stockOn the 5th of October, Matthew Lang sold around 7k shares on-market at roughly €18.62 per share. In the last 3 months, they made an even bigger sale worth €126k. Insiders have been net sellers, collectively disposing of €974k more than they bought in the last 12 months.
Board Change • Aug 05Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Lead Independent Director Kathleen Sebelius was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Jul 11Key Executive recently sold €60k worth of stockOn the 7th of July, Frank Karbe sold around 3k shares on-market at roughly €18.44 per share. This was the largest sale by an insider in the last 3 months. Frank has been a seller over the last 12 months, reducing personal holdings by €234k.
Recent Insider Transactions • Apr 09General Counsel & Corporate Secretary recently sold €171k worth of stockOn the 6th of April, Matthew Lang sold around 11k shares on-market at roughly €15.72 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €351k more than they bought in the last 12 months.
Is New 90 Day High Low • Mar 06New 90-day low: €16.40The company is down 16% from its price of €19.60 on 04 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €192 per share.
Is New 90 Day High Low • Dec 17New 90-day high: €21.40The company is up 24% from its price of €17.30 on 18 September 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €153 per share.
Is New 90 Day High Low • Dec 02New 90-day high: €20.00The company is up 17% from its price of €17.10 on 03 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €122 per share.
お知らせ • Sep 30Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate CancerMyovant Sciences announced results of an additional secondary endpoint from the Phase 3 HERO study evaluating relugolix in men with advanced prostate cancer. Relugolix did not achieve statistical superiority for castration resistance-free survival compared to leuprolide acetate in men with metastatic disease through 48 weeks. Castration-resistant prostate cancer is defined by disease progression despite achieving testosterone suppression to castrate levels (< 50 ng/dL). In the subgroup of men with metastatic disease treated with relugolix, 74% were castration-resistance free through 48 weeks compared to 75% men treated with leuprolide acetate (HR = 1.03 [95% CI: 0.68-1.57]; p = 0.84). In the secondary endpoint analysis, castration resistance-free survival was defined as the time from first dose to prostate-specific antigen (PSA) progression per the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria or death from any cause. PSA progression was defined as a PSA increase = 25% and = 2 ng/mL above the nadir, and confirmed by a second PSA value = 3 weeks later.
お知らせ • Sep 24Myovant Sciences Launches 'Forward for Health Equity' Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine FibroidsMyovant Sciences announced the launch of its 'Forward for Health Equity' grant program. The program will provide funding to nonprofit healthcare organizations with innovative projects focused on improving healthcare access, with an initial focus on reducing racial disparities in prostate cancer and uterine fibroids in the U.S.Myovant will award as many as four grants of up to $50,000 each, for a total of $200,000. Prostate cancer is the second deadliest cancer in men in the U.S. and has the largest racial disparity of any major cancer, killing Black men twice as often as white men. Uterine fibroids can cause debilitating symptoms such as heavy menstrual bleeding and pain, leading to over 250,000 hysterectomies each year in the U.S., with Black women more likely to undergo more invasive surgical procedures. Studies have also shown that Black men and women have less access to healthcare, and access issues such as lack of insurance coverage have been shown to contribute to the racial disparities in prostate cancer and uterine fibroids. Myovant previously launched the Female Forward Together coalition in partnership with Evidation Health, Flo Health, HealthyWomen, and PERIOD, with coalition projects including the development of a digital tool to evaluate menstrual blood loss and the creation of a storytelling initiative to reduce stigma around menstruation. Myovant also recently launched the Forward Momentum coalition in partnership with BlackDoctor.org, Evidation Health, and Movember to improve representation of Black men and women in research studies and to develop digital tools for men with prostate cancer. The “Forward for Health Equity” grant program will accept applications through December 31, 2020. Applicants must be U.S.-based nonprofit healthcare organizations. Applicants may not be individual healthcare professionals. Applications will be evaluated based on 1) greatest potential to improve health equity, 2) degree of innovation, and 3) focus on healthcare access. Applications will be reviewed by a committee consisting of Myovant employees and external leaders and advocates.
Is New 90 Day High Low • Sep 23New 90-day high: €19.40The company is up 10.0% from its price of €17.70 on 25 June 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €113 per share.
お知らせ • Sep 15Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 Liberty Program and from Prospective Observational StudyMyovant Sciences announced the presentation of one-year data on bone mineral density (BMD) from the Phase 3 LIBERTY program evaluating the safety and efficacy of once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with uterine fibroids. The BMD results from the LIBERTY program demonstrated maintenance of BMD through one year and were consistent with those observed in a separate prospective observational study of untreated, age-matched women with uterine fibroids. The findings were presented at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event, held September 11-15, 2020. Details of the presentations are as follows: Relugolix Combination Therapy Preserves Bone Mass in Patients with Uterine Fibroids: Results from Phase 3 LIBERTY Program (Abstract # P-641). The Phase 3 LIBERTY program evaluated the safety and efficacy of once-daily relugolix combination therapy in premenopausal women with heavy menstrual bleeding due to uterine fibroids. The program met its primary endpoints and demonstrated that relugolix combination therapy significantly reduced menstrual blood loss and pain. In this analysis, pooled data from 768 women in the LIBERTY 1 and LIBERTY 2 studies showed that mean changes in lumbar spine bone mineral density (LS BMD) were comparable for relugolix combination therapy and placebo (Week 12: -0.63% vs. 0.34%; Week 24: -0.23% vs. 0.18%, respectively). Evaluation of Relugolix Combination Therapy to Maintain Bone Mass in Women with Uterine Fibroids Through 52 Weeks: LIBERTY Long-Term Extension Study (Abstract # P-639). Eligible women who completed the LIBERTY 1 or LIBERTY 2 studies were offered the opportunity to enroll in an active treatment extension study in which all women received relugolix combination therapy for an additional 28-week period, for a total treatment period of up to 52 weeks. In this analysis, data from 163 women who entered the extension study after receiving 24 weeks of relugolix combination therapy demonstrated maintenance of BMD through 52 weeks of treatment (Week 52: LS BMD -0.80%). A Prospective Observational Study of Bone Mineral Density in Premenopausal Women with Uterine Fibroids (Abstract # P-552). This prospective observational study was designed to characterize longitudinal BMD in 262 premenopausal women with uterine fibroids. Mean LS BMD showed minimal changes over the 52-week observational period (0% at Week 24 and -0.41% at Week 52). Relugolix combination tablet is under review by the U.S. Food and Drug Administration (FDA) for the treatment of women with uterine fibroids, with a target action date of June 1, 2021. Myovant submitted a Marketing Authorization Application to the European Medicines Agency in March 2020 for relugolix combination tablet in uterine fibroids. Additionally, relugolix (120 mg) is under Priority Review by the FDA for the treatment of men with advanced prostate cancer, with a target action date of December 20, 2020. Myovant has also reported positive data from two replicate Phase 3 studies evaluating relugolix combination therapy in women with endometriosis. Myovant’s Phase 3 clinical program for uterine fibroids consisted of two multinational, replicate pivotal clinical studies (LIBERTY 1 and LIBERTY 2) of relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with heavy menstrual bleeding associated with uterine fibroids for 24 weeks. Eligible women who completed the LIBERTY 1 or LIBERTY 2 studies were offered the opportunity to enroll in an active treatment extension study in which all women received relugolix combination therapy for an additional 28-week period for a total treatment period of 52 weeks, designed to evaluate the safety and efficacy of longer-term treatment. Upon completion of this 52-week total treatment period, eligible women could elect to participate in a second 52-week randomized withdrawal study designed to provide two-year safety and efficacy data on relugolix combination therapy and to evaluate the need for maintenance therapy. Across studies, a response was defined as a menstrual blood loss volume of less than 80 mL and a 50% or greater reduction from baseline in menstrual blood loss volume during the last 35 days of treatment measured using the alkaline hematin method. LIBERTY 1 and 2 met the primary endpoint (p < 0.0001) with 73.4% and 71.2% of women receiving relugolix combination therapy achieving the responder criteria compared with 18.9% and 14.7% of women receiving placebo at 24 weeks, respectively. On average, women receiving relugolix combination therapy in both studies experienced an 84.3% reduction in menstrual blood loss from baseline (p < 0.0001). Bone mineral density was comparable between the relugolix combination therapy and placebo groups in LIBERTY 1 and 2. The distribution of the change in bone mineral density, including outliers, was similar for the relugolix combination therapy and placebo groups at 24 weeks, as assessed by dual energy x-ray absorptiometry (DXA). The overall incidence of adverse events in the relugolix combination and placebo groups was comparable in both studies. The open-label extension study also met the primary endpoint with relugolix combination therapy demonstrating an 87.7% response rate at one year, showing the durability of the response observed in LIBERTY 1 and 2. In addition, women experienced, on average, an 89.9% reduction in menstrual blood loss from baseline. Changes in bone mineral density through one year, as assessed by DXA every three months, were consistent with LIBERTY 1 and 2. The incidence of adverse events over one year was consistent with that observed in LIBERTY 1 and 2, with no new safety signals observed.